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Cytoskeletal rearrangementOsteoporosis is an aging-associated disease requiring better therapeutic modality. Eupatilin is a major ﬂa-
vonoid from Artemisia plants such as Artemisia princeps and Artemisia argyiwhich has been reported to pos-
sess various beneﬁcial biological effects including anti-inﬂammation, anti-tumor, anti-cancer, anti-allergy,
and anti-oxidation activity. Complete blockade of RANK-dependent osteoclastogenesis was accomplished
upon stimulation prior to the receptor activator of nuclear factor κB (RANK)-ligand (RANKL) treatment
or post-stimulation of bone marrow macrophages (BMCs) in the presence of RANKL with eupatilin. This
blockade was accompanied by inhibition of rapid phosphorylation of Akt, GSK3β, ERK and IκB as well as
downregulation of c-Fos and NFATc1 at protein, suggesting that transcriptional suppression is a key mech-
anism for anti-osteoclastogenesis. Transient reporter assays or gain of function assays conﬁrmed that
eupatilin was a potent transcriptional inhibitor in osteoclasts (OC). Surprisingly, when mature osteoclasts
were cultured on bone scaffolds in the presence of eupatilin, bone resorption activity was also completely
blocked by dismantling the actin rings, suggesting that another major acting site of eupatilin is cytoskeletal
rearrangement. The eupatilin-treated mature osteoclasts revealed a shrunken cytoplasm and accumulation
of multi-nuclei, eventually becoming ﬁbroblast-like cells. No apoptosis occurred. Inhibition of phosphory-
lation of coﬁlin by eupatilin suggests that actin may play an important role in the morphological change
of multinucleated cells (MNCs). Human OC similarly responded to eupatilin. However, eupatilin has no
effects on osteoblast differentiation and shows cytotoxicity on osteoblast in the concentration of 50 μM.
When eupatilin was administered to LPS-induced osteoporotic mice after manifestation of osteoporosis,
it prevented bone loss. Ovariectomized (OVX) mice remarkably exhibited bone protection effects. Taken to-
gether, eupatilin is an effective versatile therapeutic intervention for osteoporosis via; 1) transcriptional
suppression of c-Fos and NFATc1 of differentiating OC and 2) inhibition of actin rearrangement of pathogen-
ic MNCs.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).is, Histone deacetylase inhibitors; RANK, the receptor activator of nuclear factor κB; RANKL, RANK ligand; M-CSF, macrophage
ne serum; α-MEM, α-minimum essential medium; MNCs, multinucleated cells; NFATc1, nuclear factor of activated T cells c1;
ages; TRAP, tartrate-resistant acid phosphate; XTT, sodium3’-[1-(phenyl-aminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-
ontacting 0.1% Tween-20; ALP, alkaline phosphatase; LPS, lipopolysaccharide; OVX, ovariectomized; μCT, micro-computed to-
iation; SE, standard error.
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Osteoporosis is an aging-associated disease requiring unmet
medical needs. Osteoblasts (OBs) and osteoclasts (OCs) are major
players for regulated bone formation and/or bone loss as a homeostatic
balance for differentiation of bone progenitor cells (Geusens et al.,
2014). Uncontrolled expansion of OCs due to physiological changes
such as menopause or inﬂammation leads to osteoporosis. In addi-
tion, in generalized bone diseases, OCs seem to be engaged in the
process of bone tumor metastasis (Suda et al., 1999). Currently,
bisphosphonate-derivatives or calcitonin are major therapeutics
but have apparent disadvantages such as non-metabolized matter.
Although receptor activator of nuclear factor κB (RANK)-ligand
(RANKL) antibody treatment is being used and anti-sclerostin
(SOST) antibody treatment may be soon available to osteoporosis,
costs or their long-term safety remains to be explored given that
RANKL is involved in dendritic cell function and SOST seems to be
involved in Wnt signaling (Williamson et al., 2002; Semënov et al.,
2005). Hence, the necessity for novel therapeutic interventions is
evident for osteoporosis. Histone deacetylase inhibitors (HDACis)
have exerted potent osteogenic potential related to stability of
Runx2 by deacetylases (Kim et al., 2011; Jeon et al., 2006). As such
there have been a great number of small molecules or natural
products that have been shown to affect osteoclastogenesis (Kim
et al., 2014a,b; Lee et al., 2014; Kwak et al., 2010). Although the
RANKL/RANK axis is the master regulator for osteoclastogenesis,
precise underlying mechanisms for contribution of many coupling
factors such as SOST, semaphorin, OSCAR, FcR or OC-STAMP to oste-
oclastogenesis remains to be explored (Honma et al., 2014). In
particular, the formation of an actin ring, which is the hallmark of
OC function or bone resorptionmechanism has not fully appreciated.
Therefore, it is possible that there exists a myriad of small molecules
affecting osteoclastogenesis acting on this wide range of coupling
factors, thereby dampening down formation of multinucleated cells
(MNCs) or bone resorption. The RANK/RANKL axis is the master
regulator for formation of TRAP+ OCs (Takayanagi et al., 2002). De-
velopment of a versatile therapeutic intervention via combinatorial
blockade for both the early differentiation process and later bone
resorption of OCs could create a powerful therapeutic modality.
Artemisia has been safely used for many inﬂammatory diseases
as herbal extracts for a few thousand years (van der Kooy and
Sullivan, 2013; Cha et al., 2009; Choi et al., 2011; Kim et al., 2009;
Ho et al., 2014). Eupatilin is an O-methylated ﬂavonoid (Son et al.,
2013). A great number of ﬂavonoids have anti-oxidant potential or
apoptotic effects on tumor cells (Ji et al., 2014). Although several
ﬂavonoids except some species have been demonstrated to have
osteogenic capabilities, underlying molecular mechanisms remain
to be largely unexplored (Yamaguchi et al., 2007). Also, a recent re-
port demonstrated the anti-arthritic effect of eupatilin on collagen-
induced arthritis (CIA) mice model (Kim et al., 2015). However, the
relationship between eupatilin and osteoporotic mice model has
not been explored.
Here, we show that eupatilin is a potent inhibitor of the formation of
MNCs in vitro via both the suppression of key transcription factors and
polymerization actin ring formation. As such, the in vivo administration
of eupatilin into mice substantially prevented the onset of bone loss
caused by ovariectomy or inﬂammation. Eupatilin was also able to
completely block formation of human MNCs in vitro.
2. Materials and methods
2.1. Mice and reagents
Male, 5-week-old ICR mice were purchased from Damul Science
(Daejeon, Korea). Ten-week-old OVX mice were purchased from
Central Lab. Animal Inc. (Seoul, Korea).Micewere kept in a temperature(22 °C–24 °C) and humidity (55%–60%) controlled environment with a
12 h light/dark cycle. All experiments were performed in accordance
with guidelines for animal experimentation of the Institute Committee
of Wonkwang University. Eupatilin was obtained from DONG-A
PHARM (Seoul, Korea). Soluble, recombinant human M-CSF and human
RANKL were obtained from PeproTech EC, Ltd. (London, UK). Anti-Akt,
anti-phospho-Akt, anti-GSK3β, anti-phospho-GSK3β, anti-IκB, anti-
phospho-IκB, anti-Coﬁlin, anti-phospho-Coﬁlin, anti-p38, anti-phospho-
p38, anti-ERK, anti-phospho-ERK, anti-JNK, and anti-phospho-JNK
antibodies were purchased from Cell Signaling Technology, Inc. (Beverly,
MA, USA). Anti-c-Fos, and anti-NFATc1 antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). A monoclonal β-actin
antibody was obtained from Sigma (St. Louis, MO, USA). Fetal bovine
serum (FBS), α-minimum essential medium (α-MEM), and penicillin/
streptomycin were purchased from Gibco BRL (Grand Island, NY, USA).
All other chemicals were of analytical grade or complied with the
standards required for cell culture.
2.2. Human and mouse bone marrow macrophage preparation
Human bonemarrow cells (BMCs) were obtained from healthy vol-
unteers and were separated by density gradient centrifugation using
Ficoll–Histopaque (Sigma-Aldrich, St. Louis, MO, USA). These cells
were cultured for 7 days in the presence of M-CSF (100 ng/mL).
Mouse BMCs obtained from 10-week-old C57BL/6J female mice by
ﬂushing the femurs and tibias were seeded on culture dishes in α-
MEM supplemented with 10% FBS and M-CSF (10 ng/mL). Non-
adherent cells were transferred to 10-cm petri dishes and cultured
in the presence of M-CSF (30 ng/mL) for an additional 3 days.
2.3. In vitro osteoclastogenesis assay
BMCs were obtained from 5-week-oldmale ICR mice by ﬂushing fe-
murs and tibias with α-MEM supplemented with 10% FBS, penicillin
(100U/mL), and streptomycin (100 μg/mL) and fromhuman bonemar-
row. To obtain BMMs, BMCs were seeded on culture dishes in α-MEM
supplemented with 10% FBS and M-CSF (10 ng/mL) and cultured for
1 day. Non-adherent cells were transferred to 10-cm petri dishes and
further cultured in the presence of M-CSF (30 ng/mL) for 3 days. After
non-adherent cells were removed, adherent cells were used as BMCs,
which contain osteoclast precursors. To generate osteoclasts from
these BMCs, cells were seeded in a 48-well plate (3.5 × 104 cells/well)
in complete medium containing M-CSF (30 ng/mL) and RANKL
(100 ng/mL) and cultured for 4 days with or without eupatilin. The
cells were ﬁxed in 3.7% formalin for 10 min, permeabilized with 0.1%
Triton X-100, and then stained with TRAP (Sigma). TRAP-positive
MNCs with more than three nuclei were counted as osteoclasts.
2.4. Pre-treatment with eupatilin in osteoclastogenesis assay
Bone marrow macrophages (BMMs) were cultured in the presence
only of M-CSF (10 ng/mL) for 1 day. After pre-treatment of BMMs
with eupatilin for the indicated times, the cells were cultured in a
new medium containing M-CSF (30 ng/mL) and RANKL (100 ng/mL)
for 3 or 4 days. The cells were stained with a TRAP solution as de-
scribed above. TRAP-positive osteoclasts with more than ﬁve nuclei
and multinucleated cells with more than three nuclei were counted
as osteoclasts.
2.5. Post-treatment with eupatilin in osteoclastogenesis assay
BMMs were cultured in the presence of M-CSF (30 ng/mL) and
RANKL (100 ng/mL) for 3 days. Before TRAP staining, BMMs were
post-treated with eupatilin for the indicated times and then cells were
stained with a TRAP solution as described above.
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The XTT (sodium3′-[1-(phenyl-aminocarbonyl)-3,4-tetrazolium]-
bis(4-methoxy-6-nitro) assay was performed to examine the effects of
eupatilin on the viability of BMCs. Mouse BMCs (1 × 104 cells/well)
were seeded in 96-well plates with various concentrations of eupatilin
and incubated for 3 days in the presence of M-CSF (30 ng/mL). Then,
XTT solution (50 μL) was added to each well and incubated for 4 h.
The plate was read at 450 nmwith an ELISA reader (Molecular Devices,
CA, USA) and interpolated from a standard curve.2.7. Western blot analysis and quantitative real-time polymerase chain
reaction (RT-PCR) analysis
Western blot analysis, and quantitative RT-PCR were performed
as described previously (Kim et al., 2014c). We performed Western
blotting by using 1:1000 dilution of primary antibodies with a source
of rabbit or mouse reconstituted at 1 mg/mL and 1:3000 anti-rabbit
and -mouse secondary antibodies reconstituted at 0.4 mg/mL. The ex-
pression data of quantitative RT-PCR were calculated from the cycle
threshold (Ct) value using the delta–delta Ct (Livak) method by using
those primer sets as shown in Table 1.2.8. Pit formation assay
BMCs (1 × 107 cells) and primary osteoblasts (1 × 106 cells) were
seeded on collagen gel-coated culture dishes and cultured for 7 days
in the presence of 10−8 M 1,25-dihydroxyvitamin D3 (Sigma) and
10−6 M prostaglandin E2 (PGE2) (Sigma). The co-cultured cells were
detached by 0.1% collagenase treatment at 37 °C for 10 min and were
then replated on hydroxyapatite-coated plates (Corning, Corning, NY,
USA) for 24 h and dentin slices for 48 h. Cells attached to the plates
or dentin slices were removed and the total resorption pits were
photographed by microscopy and analyzed using Image-Pro Plus
version 4.0 (Media Cybernetics, Silver Spring, MD, USA).Table 1
Primer sequences for real-time RT-PCR.
TRAP Forward: 5′-TCA TGG GTG GTG CTG CT-3′
Reverse: 5′-GCC CAC AGC CAC AAA TCT-3′
c-Fos Forward: 5′-GGT GAA GAC CGT GTC AGG AG-3′
Reverse: 5′-TAT TCC GTT CCC TTC GGA TT-3′
NFATc1 Forward: 5′-GAG TAC ACC TTC CAG CAC CTT-3′
Reverse: 5′-TAT GAT GTC GGG GAA AGA GA-3′
Cathepsin K Forward: 5′-CCA GTG GGA GCT ATG GAA GA-3′
Reverse: 5′-CTC CAG GTT ATG GGC AGA GA -3′
OSCAR Forward: 5′-GGA ATG GTC CTC ATC TGC TT-3′
Reverse: 5′-TCC AGG CAG TCT CTT CAT TTT-3′
DC-STAMP Forward: 5′-TCC TCC ATG AAC AAA CAG TTC CA-3′
Reverse: 5′-AGA CGT GGT TTA GGA ATG CAG CTC-3′
OC-STAMP Forward: 5′-ATG AGG ACC ATC AGG GCA GCC ACG-3′
Reverse: 5′-GGA GAA GCT GGG TCA GTA GTT CGT-3′
Integrin αν Forward: 5′-ACA AGC TCA CTC CCA TCA CC-3′
Reverse: 5′-ATA TGA GCC TGC CGA CTG AC-3′
Integrin β3 Forward: 5′-GGA GTG GCT GAT CCA GAT GT-3′
Reverse: 5′-TCT GAC CAT CTT CCC TGT CC-3′
ICAM-1 Forward: 5′-CAT GCC TTA GCA GCT GAA CA-3′
Reverse: 5′-AGC TTG CAC GAC CCT TCT AA-3′
TESK1 Forward: 5′-AAG AAC ACG CAT TGG CCT AC-3′
Reverse: 5′-CGT CTT GAG AGT GCA CCG TA-3′
LIMK2 Forward: 5′-GAC CAG CTA CGG CTA GAT GC-3′
Reverse: 5′-TCA GTG TCC CCT CCT GAT TC-3′
Coﬁlin Forward: 5′-CCT CTG GTG TGG CTG TCT CT-3′
Reverse: 5′-GCC TTC TTG CGT TTC TTC AC-3′
GAPDH Forward: 5′-TCA AGA AGG TGG TGA AGC AG-3′
Reverse: 5′-GGT GGA GGA GTG GGT GTC-3′2.9. Osteoblastic cell culture and assays
To culture osteoblasts, calvarias of neonatal mice were digested
with 0.1% collagenase and 0.2% dispase 5 times, and cells isolated in
the last 3 digestions were combined and cultured inα-MEM containing
10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin. To measure
alkaline phosphatase (ALP) activity, primary osteoblasts were inoculat-
ed at a density of 2 × 104 cells/well and cultured in the absence or
presence of 50 μg/mL ascorbic acid and 10 mM β-glycerol phosphate.
On differentiation day 7, cells were sonicated in 50 mM Tris–HCl buffer
(pH 7.4) containing 1% Triton X-100, 150 mM NaCl, and 1 mM EDTA.
Then, 100 μL of substrate (p-nitrophenylphosphate) (Sigma) was
added to the cells, and the plate was incubated for 30 min at 37 °C.
The amount of p-nitrophenol released was determined by measuring
absorbance at 405 nm using a microplate reader. For ALP staining,
cells were ﬁxed in 70% ethanol and stained for 10–20 min with a solu-
tion containing 0.01% naphthol, AS-MX phosphate, 1% N,N-dimethyl
formamide, and 0.06% fast blue BB (Sigma).
2.10. Retrovirus preparation and infection
Retroviral vectors pMX-IRES-EGFP, pMX-cFos-IRES-EGFP, pMX-
constitutively active (CA)-NFATc1-IRES-EGFP, pMX-CA-IKKβ-IRES-
EGFP, and pMX-Akt-IRES-EGFP were used for transient transfection
of these pMX vectors into Plat-E retroviral packaging cells using X-
tremeGENE 9 (Roche, Nutley, NJ, USA) according to the manufacturer's
protocol. After incubation in a freshmedium for 2 days, culture superna-
tants of the retrovirus-producing cells were collected. For retroviral
infection, non-adherent BMCs were cultured in M-CSF (30 ng/mL) for
2 days. BMMs were incubated with viral supernatant pMX-IRES-EGFP,
pMX-cFos-IRES-EGFP, pMX-CA-NFATc1-IRES-EGFP, pMX-CA-IKKβ-
IRES-EGFP, and pMX-Akt-IRES-EGFP virus-producing Plat-E cells
together with polybrene (10 μg/mL) and M-CSF (30 ng/mL) for 6 h.
The infection efﬁciency of retroviruses was determined by green
ﬂuorescent protein expression, and was always greater than 80%.
After infection, BMMs were induced to differentiate in the presence of
M-CSF (30 ng/mL) and RANKL (100 ng/mL) for 4 days. Osteoclast
formation was detected by TRAP staining.
2.11. Immunoﬂuorescence confocal microscopy
BMMs were incubated with M-CSF (30 ng/mL) and RANKL
(100 ng/mL) in the presence of DMSO or eupatilin. After 3 days,
a culture medium was replaced with a fresh medium containing
the same ingredient. One day later, the cells were ﬁxed in 3.7% formalin
for 20min, permeabilized with 0.1% Triton X-100 for 15min, incubated
with 0.25% bovine serum albumin for 30 min, and stained with
phalloidin andDAPI solution to visualize F-actin and nuclei, respectively
(Life Technology, Seoul, Korea). Fluorescence detection of cells was ob-
served under a laser scanning confocal microscope (Olympus FV1200,
Japan). Images were analyzed by the Image-Pro Plus software (USA)
and are representative of ﬁve experiments.
2.12. Mice and treatments
To study the preventive effect of eupatilin on lipopolysaccharide
(LPS)-induced osteoclast formation in vivo, ICR mice were di-
vided into 4 experimental groups comprised of 5 mice each: the
phosphatebuffered saline (PBS)-treated (Control), only LPS-treated,
only eupatilin-treated, and LPS and eupatilin-treated groups. Eupatilin
(10 mg/kg) or PBS was administered orally 1 day before LPS injection
(5 mg/kg). Eupatilin or PBS was administered orally every other day
for 8 days. LPS was injected intraperitoneally on days 1 and 4. The
mice were killed after 8 days, and the left femurs were analyzed by
high-resolution micro-computed tomography (μ-CT). The right femurs
were ﬁxed in 4% paraformaldehyde (Sigma) for 1 day, decalciﬁed
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μm thick) were prepared using a Leica microtome RM2145 (Leica
Microsystems, Bannockburn, IL, USA), and were stained with hema-
toxylin and eosin (H&E). To conﬁrm the therapeutic effect of
eupatilin on LPS-induced bone loss in vivo, ICR mice were divided
into 6 experimental groups comprised of 5 mice each: PBS-treated
(Control), LPS-treated, and LPS plus eupatilin-treated groups.
Eupatilin (10 mg/kg) or PBS was administered orally every day
from 4, 6, or 8 days. LPS was injected intraperitoneally on days 1
and 4. Mice were killed after 5 days (only LPS-treated Day 5 group)
or 10 days. Mice were killed after 10 days, and the left femurs
were analyzed by high-resolution μ-CT. We further assessed the
effect of eupatilin on ovariectomy (OVX)-induced bone loss. Eight-
week-old female C57BL/6 mice were either 6 sham-operated
mice or 12 OVX mice. OVX mice were divided into two groups:
OVX control (PBS) and eupatilin (10 mg/kg) groups. After, eupatilin
was administrated orally for 4 weeks. The μCT images, analysis of
several parameters, and histological data were acquired as described
above.Fig. 1. Potent anti-osteoclastogenic capability of eupatilin and effects of eupatilin on cytotoxicity
(30 ng/mL) and RANKL (100 ng/mL) with control media or eupatilin. Cells were ﬁxed and stain
Themagniﬁcation of images is 10×. (B) Cell viability was determined by XTT assay using BMCs.
the presence of 50 μg/mL ascorbic acid and 10mM β-glycerol phosphate. ALP positive cells were
for 4 days in the presence of M-CSF and RANKL with eupatilin (50 μM) or control (DMSO). Cel
stained with rhodamine phalloidin for actin ring. The magniﬁcation of images is 10×.2.13. μCT analysis
Femur metaphysic regions were scanned using a high-resolution
μCT (NFR-Polaris-S160; Nanofocus Ray, Iksan, Korea) with a source
voltage of 60 kVp, current of 114 μA and 7 μm isotropic resolution.
Femur scans were performed from the growth plate proximally to
2 mm, with 350 sections per scan. Bone histomorphometric analyses
were performed with μCT data using INFINITT-Xelis software (INFINITT
Healthcare, Seoul, Korea). Structural parameters were trabecular bone
volume/total volume (BV/TV, %), trabecular thickness (Tb·Th, μm), tra-
becular separation (Tb·Sp, μm), and trabecular number (Tb·N, 1/mm).
2.14. Statistical analyses
Experiments were conducted at least three times, and the data are
expressed as the mean ± standard deviation (SD) or the mean ± stan-
dard error (SE). All statistical analyses were performed by using the
Statistical Package for the Social Sciences Software (SPSS; Korean
version 14.0). Most statistical differences were analyzed using one-and osteoblasogenesis. (A)Mouse BMCswere cultured for 4 days in the presence ofM-CSF
ed with TRAP solution (upper). TRAP-positive MNCs were counted as osteoclasts (lower).
(C) Primary osteoblasts were treatedwith various concentrations of eupatilin for 7 days in
stainedwith ALP solution. ***P b 0.001 versus the control. (D)Mouse BMCswere cultured
ls were ﬁxed with 3.7% formalin in PBS, permeabilized with 0.1% Triton X-100 in PBS and
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were considered statistically signiﬁcant.
3. Results
3.1. Eupatilin is a potent inhibitor of NFATc1 transcription
To see if eupatilin exerts effects on bone homeostasis we stimulated
mouse BMCswith various concentrations of eupatilin in the presence of
RANKL (100 ng/mL) andwere able to notice a potent inhibitory effect of
eupatilin on osteoclastogenesis; complete absence of TRAP+ OC was
seen at 50 μM eupatilin (***P b 0.001) (Fig. 1A). When using BMCs, no
or marginal cytotoxic effect was associated with eupatilin by detectingFig. 2. Effects of eupatilin on downregulation of OC-speciﬁc genes involved in transcription r
eupatilin (50 μM) for 1 h and with RANKL (100 ng/mL) for the indicated times. Expression o
and αv (G–I), and ICAM-1 (J) mRNA level was analyzed real-time RT-PCR.the absorbance optical density from XTT assay based on the medium
(Fig. 1B). Formation of OB remained unaffected at 25 μMor signiﬁcantly
downregulated at 50 μM based upon ALP activity (***P b 0.001)
(Fig. 1C), suggesting that eupatilin may preferentially act on OCs
and show cytotoxicity on OB at 50 μM. Eupatilin completely blocked
F-actin formation (Fig. 1D), suggesting that eupatilin, at least, affects
cytoskeleton rearrangement. Real-time RT-PCR experiments showed
that c-Fos and NFATc1 mRNAs were signiﬁcantly downregulated in a
time-dependent manner and no TRAPmRNA was detected, conﬁrming
the TRAP staining results. (*P b 0.05, **P b 0.01, and ***P b 0.001)
(Fig. 2A–C). Complete suppression of OSCAR, OC-STAMP and cathepsin
K transcription was achieved (**P b 0.01, and ***P b 0.001) (Fig. 2D–F)
and transcription of DC-STAMP, Integrin β3, Integrin αv and ICAM-1epression of NFATC1 and differentiation of OC. BMMs were pre-treated with or without
f c-Fos, NFATc1, TRAP (A–C), OSCAR, OC-STAMP, cathepsin K (D–F), DC-STAMP, Integrin β3
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(Fig. 2G–J). This may indicate that elimination of cathepsin K transcrip-
tion by eupatilin has an inhibitory ability on bone resorption associated
with eupatilin. The phosphorylation status of several early signal trans-
ducers was examined upon eupatilin stimulation. Eupatilin markedly
inhibited phosphorylation of Akt, GSK3β, IκB (Fig. 3A–B) and to a lesser
extent blocked that of ERK at 30min after stimulation (Fig. 3C) whereas
neither p38 nor JNK was affected by eupatilin. This suggests that these
kinases may not be linked to activity of eupatilin in terms of anti-
osteoclastogenesis (Fig. 3C). It should be noted that c-Fos and NFATc1
protein levels were substantially reduced (Fig. 3D). To substantiate
these inhibitory mechanisms restoration experiments were
performed. In vitro osteoclastogenesis assays were conducted with the
use of overexpression of constitutively active or wild type transcription
factors in the presence of 25 μM eupatilin. No TRAP+ MNCs were
recovered even after overexpression of transcription factors. While
overexpression of constitutive c-Fos or NFATc1 demonstrated a signiﬁ-
cant restoration (#P b 0.05, ##P b 0.01, and ***P b 0.001) (Fig. 4A–B)
only a partial restoration of TRAP+MNCs resulted from overexpressing
constitutive active IκB andAkt (*P b 0.05 and ***P b 0.001) (Fig. 4C-D). In
particular, overexpression of constitutive NFATc1 restore MNCs to a
greater extent than other genes overexpressed. One of themajor signal-
ing read-outs elicited by RANKL is NF-κB activation, contributing to
induction of the transcription of NFATc1. To see whether eupatilin
inhibits NF-κB activation, a ligand-dependent reporter assay was
conducted as seen in Fig. 4E (###P b 0.001 and ***P b 0.001) Eupatilin
was able to signiﬁcantly attenuate luciferase activities in both a
ligand-dependent and dose-dependent manner, strongly suggesting
that transcriptional repression of NF-κB is a way by which eupatilin
blocks osteoclastogenesis, presumably culminating in induction of
NFATc1. Taken together, these data suggest that eupatilin effectively
blocks osteoclastogenesis via rapidly blunting phosphorylation of Akt,
GSK3β, ERK or NF-κB, resulting in downregulation of NFATc1.Fig. 3. Effects of eupatilin on phosphorylation of kinases or transcription factors, and on decrease
for 1 h in the presence of M-CSF (30 ng/mL) and were then stimulatedwith RANKL (100 ng/mL
with the indicated antibodies. (A–C) phosphorylation of Akt, GSK3β, IκB, ERK, respectively, an3.2. Eupatilin is a potent inhibitor of actin polymerization of MNCs
Since eupatiln was able to signiﬁcantly attenuate cathepsin K tran-
scription and dismantle F-actin formation, we hypothesized that
eupatilin could also block bone-resorption capability of MNCs. MNCs
were cultured on hydroxyapatitite or dentin scaffold in the presence
of varying concentrations of eupatilin for 24 h. Pit formation and bone
resorbed area were enumerated. As shown in Fig. 5A–B, treatment of
these MNCs with 25 μM or 50 μM eupatilin completely eliminated pit
formation and bone-resorption capability associated with MNCs
(**P b 0.01, and ***P b 0.001). We initially noticed that those eupatilin-
treated MNCs on dentins underwent substantial morphological change
by deforming cell membrane into an irregular shape. This may raise
the question that the strong blockade of bone resorption by eupatilin
is not due to cathepsin K, since complete transcriptional suppression
of cathepsin K occurred as shown in the earlier real-time RT-PCR exper-
iments. However, fully functional MNCs were situated at the dentin
surface, and exocytosis of cathepsin K might have taken place. Hence,
actin polymerization might be a key milestone linked to eupatilin-
mediated inhibition of bone resorption.We further determined wheth-
er eupatilin can dismantle actin ring structure/formation by visualizing
phallodin probe. Confocal imaging analysis suggests that treatment
with eupatilin completely dismantled actin ring as shown in Fig. 5C.
Since DAPI staining remained intact it appears that eupatilin may
not cause apoptosis. Since the duration of complete inhibition of
the bone resorption took placed within 24 h we asked whether pre-
treatment of mouse BMMs with eupatilin would lead to inhibition of
differentiation of OC. As shown in Fig. 5D, eupatilin pre-treatment for
only 3 h caused a substantial attenuation of generation of TRAP+ OC
and TRAP+MNCs. At 6 h near complete inhibition was noted, suggest-
ing that a brief exposure of BMMs to eupatilin gives rise to amomentum
responsible for blocking commitment ofmacrophages to OC and further
to MNCs via engagement of RANK with RANKL (*P b 0.05 ***P b 0.001).s in c-Fos andNFATc1.Mouse BMCswere pre-treatedwith the eupatilin (50 μM)or control
) for the indicated time points. Whole-cell lysates were subjected toWestern blot analysis
d (D) attenuated protein levels of c-Fos and NFATc1.
Fig. 4. Restoration of osteoclastogenic potential via overexpression. (A–B) Mouse BMMs were infected with retroviruses bearing c-Fos, a constitutively active form of NFATc1 or vehicle.
Infected BMMs were cultured with or without eupatilin (25 μM) in the presence of M-CSF (30 ng/mL) and RANKL (100 ng/mL) for 4 days. TRAP-positive multinucleated osteoclasts
were counted. (C–D) Mouse BMMs were infected with retroviruses bearing a constitutively active form of IκB, a catalytically active Akt or vehicle. Differentiation and TRAP staining
was conducted as described above. The magniﬁcation of images is 10×. (E) Mouse RANK-expressing 293T cells were transfected with NF-κB-driven luciferase and stimulated with
RANKL (100 ng/mL) or control in the increasing concentrations of eupatilin. Luciferase activities were normalized by those of β-gal.
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differentiation. Normally, fully differenced MNCs appear at 72 h upon
RANKL treatment. Indeed, at 24 h prior to complete differentiation,
during which time MNCs were being generated, eupatilin-treated
MNCs exhibited a signiﬁcant reduction of cytoplasm and accumulation
of fused nuclei as denoted by arrow bars in Fig. 5E. Observation
under high magniﬁcation power clearly showed that a vast majority of
24 h-long eupatilin-treated TRAP+ OC or MNCs shrank and yielded
ﬁbroblast-like appendages. Control TRAP+ OC was clustered, possibly
due to directed cell migration for cell fusion. Control MNCs or 6 h
eupatilin-treated MNCs contain a large cytoplasm containingdistributive multiple nuclei. Taken together, these bone resorption as-
says and imaging analysis suggests that eupatilin effectively induces
cell shape change, probably via actin depolymerization.
3.3. Effect of eupatilin on phosphorylation of coﬁlin and expression of TESK1
and LIMK2
To see if eupatilin modulates actin polymerization, phosphorylation
of coﬁlin was checked. As shown in Fig. 6A, eupatilin signiﬁcantly atten-
uated phosphorylation of coﬁlin but phosphorylated coﬁlin was
sustained until 48 h after stimulation with RANKL, suggesting that
Fig. 5. Effects of eupatilin on bone resorption and cell shape change. (A)MNCswere seeded on hydroxyapatite-coated plates and treatedwith the indicated concentrations of eupatilin for
24h or 48h. Pit areaswere quantiﬁedusing ImageJ (right). Themagniﬁcation of images is 10×. (B)MNCswere cultured on dentin slices and treatedwith eupatilin (50 μM). Resorbed areas
were stained andmeasured. Themagniﬁcation of images is 10×. (C)Mouse BMCswere cultured for 4 days in the presence ofM-CSF (30 ng/mL) and RANKL (100 ng/mL) on glass coverslip
and treatedwith control or eupatilin (50 μM). Cells were ﬁxed and stainedwith rhodamine phalloidin to detect actin ring. Images in the bottom of panelsweremergedwith the images of
upper panels including phalloidin and DAPI staining. (D) After stimulating BMMs with M-CSF (30 ng/mL), overnight BMMs were pre-treated with eupatilin (50 μM) for 1 h, 3 h or 6 h
followed by washing the stimulated cells. Cells were then stimulated with M-CSF (30 ng/mL) and RANKL (100 ng/mL) for 3 days and stained with TRAP solution. TRAP-positive OC
andMNCswere counted. Themagniﬁcation of images is 10×. (E) Mouse BMCswere differentiated intomature OC for 3 days, treatedwith eupatilin for 6 h, 12 h, or 24 h prior to complete
differentiation and stained with TRAP solution. The magniﬁcation of images is 10×. Normal or deformed MNCs are indicated with arrow bars.
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whether eupatilin may regulate two kinases, TESK1 and LIMK2. As
shown in Fig. 6B–C, basal levels TESK1 and LIMK2 were sharply down-
regulated 12 h after RANKL treatment and remained constant at these
basal levels thereafter. 1 h pre-treatment of BMMs with eupatilin
further diminished basal levels of TESK1 or LIMK2 (which is denoted
by arrows) (***P b 0.001). Another set of real-time PCR experiment
revealed that mRNA levels of these kinases rapidly dropped to basal
levels within 2 h after stimulation with RANKL (data not shown),
suggesting that downregulation of these kinases play some role in
osteoclasotogenesis within the natural RANKL/RANK axis. Hence, corre-
lation of functions of these kinases to eupatilin is obscure andhow these
kinases work on osteoclastgenesis in a concerted manner with RANK
downstream remains to be determined.
3.4. Eupatilin exhibits a potent inhibitory effect on differentiation of
human OC
To see if eupatilin was also able to block human osteoclastogenesis,
in vitro assays were performed using human OC. As shown in Fig. 7, adose-dependent inhibition of generation of TRAP+ human OC was re-
vealed in the presence of M-CSF (30 ng/mL) and RANKL (100 ng/mL),
suggesting that eupatilin treatment may be useful for the treatment of
human osteoporosis (***P b 0.001).
3.5. Potent therapeutic capabilities associated with oral administration of
eupatilin for bone regeneration in two murine osteoporotic models
The two distinct activities associated with eupatilin, namely
transcriptional suppression and inhibition of actin rearrangement,
prompted us to test whether eupatilin could effectively reduce
bone resorption in two different mouse models; 1) LPS-induced
bone loss (Negishi-Koga et al., 2011) and 2) OVX-induced bone loss
(Koga et al., 2004). Each model has two different sub-models to val-
idate effectiveness of eupatilin on bone loss as seen in Figs. 8 and 9. A
normal LPS model was conducted as shown in Fig. 8A. Eupailin per se
did not generate an overt harmful effect on control mice.
Examination of other organs has been not assessed.
For a therapeutic model, LPS was administered intra-peritoneally
into mouse at day 0. Signiﬁcant bone loss was noted at day 5, inferring
Fig. 6. Dephosphorylation of coﬁlin and rapid downregulation of TESK1 and LIMK2 in
response to eupatilin. (A) Cell lysates were prepared in the presence or absence of
eupatilin. Western blot analysis was performed with a phosphor-speciﬁc coﬁlin, total
coﬁlin, or β-actin antibody. (B–C) Mouse BMMs were pre-treated with eupatilin (50 μM)
or control for 1 h and differentiation was driven by addition of RANKL (100 ng/mL) for the
indicated time points. mRNAs were then extracted and expression of TESK1 and LIMK2
mRNA levels were analyzed with real-time RT-PCR. The mRNA levels at time zero, namely
1 h after eupatilin or control pre-treatment, were indicated with arrows for comparison.
Fig. 7. Potent inhibition of human osteoclastogenesis by eupatilin in vitro. Human BMCs
were obtained from voluntary donors and differentiated with M-CSF (30 ng/mL) and
RANKL (100 ng/mL) for 9 days with a change of same conditioned medium every
3 days. Then, human TRAP-positive osteoclasts were subjected to TRAP assay in the
presence of increasing concentrations of eupatilin or vehicle. TRAP+ human OC
(nuclei N 3) were enumerated by microscopic observation. The magniﬁcation of images
is 10×.
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followed by oral delivery of eupatilin 3 times at days 4, 6 or 8 in which
each delivery was accompanied by boost injection at every two days
till 10 days when fulminant bone loss was evident as shown Fig. 8D–E.
Surprisingly, eupatilin completely prevented bone loss in each model
(*P b 0.05, **P b 0.01, ***P b 0.001, #P b 0.05, ##P b 0.01, and ###P b
0.001) (Fig. 8C–F). Especially, it should be noted that only double oral
administrations of eupatilin at day 8 was capable of healing LPS-
induced bone loss in the therapeutic model as evident by the effects of
eupatilin on bone-related parameters that up-regulation of bone vol-
ume and downregulation of trabecular bone separation (**P b 0.01,
***P b 0.001, #P b 0.05, ##P b 0.01, and ###P b 0.001) (Fig. 3F). Two
OVX-induced bone loss models were designed such that while the
normal therapeutic model took 4 weeks for induction of osteoporosis,
an aggressive therapeutic model took an extended 8 weeks for induc-
tion of osteoporosis followed by 4 weeks treatment (Fig. 9A and D).
The aggressive model exhibited more signiﬁcant bone loss than the
normal model as shown in Fig. 9B and E. Eupatilin-treated OVX mice
exhibited a signiﬁcant restoration of bone loss as compared with sham
controls from these two models (*P b 0.05, **P b 0.01, ***P b 0.001,
and #P b 0.05) (Fig. 9C and F). Increase in bone volume and tibia number
is especially notable.4. Discussion
We observed that pre-treatment, post-treatment, or any interim
treatments of OCs with eupatilin greatly affected the biological status
of OCs. This suggests that eupatilin gives rise to multifaceted effects on
OCs. Transcriptional suppression of c-Fos or NFATc1 by eupatilin may
be restricted to OCs existing at very early differentiation stages, because
eupatilinwas able to inhibit phosphorylation of Akt, GSK3β, ERK and IκB
within 30 min. In osteoclastogenesis, several early signaling including
Akt, GSK3β, NF-κB and ERK are reported to be required for optimal
induction of NFATc1 (Feng et al., 2014). Also, it has been reported that
attenuation of calcium immobilization or inhibition of NF-κB or ERK in
part accounts for ﬂavonoid-mediated anti-osteoclastogenesis
(Yamaguchi et al., 2007; Ang et al., 2011). Althoughwe did not perform
calciumoscillationwith the treatment of eupatilin to BMMs our data are
Fig. 8. Complete regeneration of LPS-induced bone loss by eupatilin. (A) Two different strategies of bone loss induction and oral administration are shown. (B) Normal model; 5 mice or
control mice were administered eupatilin 1 day prior to the 1st LPS injection (5 mg/kg) represented by day 0. The 2nd LPS injection (5 mg/kg) was conducted on day 2 followed by daily
oral delivery of eupatilin until killed at day 8. Radiographs of the longitudinal and transverse section of the proximal femurs were obtained with a μ-CT apparatus. (C) The trabecular bone
volume/total volume (BV/TV), trabecular separation (Tb·Sp), trabecular thickness (Tb·Th), and trabecular number (Tb·N) of the femurs were determined using the μ-CT data as analyzed
with INFINITT-Xelis software. **P b 0.01 and ***P b 0.001 versus the control group, and #P b 0.05, ##P b 0.01, and ###P b 0.001 versus the LPS group. Each experiment was performed once
but some time points were conducted twice for veriﬁcation. (D) Therapeutic model; LPS (5 mg/kg) was injected at day 0 and day 4. Eupatilin was administered at day 4, day 6 or day 8
followed by daily delivery until killed. (E) The same CT was performed and analyzed as described in (B). (F) The same parameters were used for bone regeneration as described in (C).
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RANKL-dependent transient activation of NF-κB and overexpression
following restoration data clearly suggests that eupatilin is a potent in-
hibitor of induction of c-Fos or NFATc1. Although we do not delineate
the inhibition of such rapid phosphorylation of these kinases or IκB via
eupatilin it is likely that eupatilin might affect lipid kinases such as
PI3K and PDK or Ras signaling pathway. Regarding inhibition of c-Fos
as an immediate early gene, immediate early signal transducers such
as serum response factor SRF involving SAP-1 or Elk1 might be targets
for eupatilin as well (Dalton and Treisman, 1992; Miranti et al., 1995).
Action modes of rapid transcriptional repression of c-Fos or NFATc1 by
eupatilin remains to be further delineated.
Along with this transcription repression model, we observed that
contacting effect of eupatilin on OCs was prominent. Pre-treatment of
mouse BMMs with 50 μM eupatilin for only 3 h gave rise to dramatic
inhibition of OC differentiation or formation of MNCs. Even interim-
treatment or post-treatment strikingly affected cell fusion as well as
morphological changes, and eupatilin completely blocked pit formation.
The rhodamine–phalloidin imaging feature strongly suggests thatcytoskeletal rearrangement of OCs induced by eupatilin may be an
important mechanism through which formation of MNCs is affected,
as cells became morphologically transformed into ﬁbroblast-like cells.
While this manuscript was in preparation, Li et al. reported that
naringin, a ﬂavonoid, induced apoptosis of OCs via mitochondrial
dismantling (Li et al., 2014). However, we did see intact nuclei via
DAPI whereas actin ring was markedly prevented from forming.
Both inhibition of F-actin formation and bone resorption, and phos-
phorylation of coﬁlin by eupatilin strongly indicate that another
major action mode is a cytoskeletal change through alteration of
actin. Previously, it was reported that TESK1 and LIMK2 play a pivotal
role in reprogramming mouse embryonic ﬁbroblasts into embryonic
stem cells via phosphorylation of coﬁlin which is responsible for
actin polymerization (Sakurai et al., 2014). Since eupatilin treatment
was unable to shut down sustained phosphorylation of coﬁlin until
48 h we believe that there could be an OC-speciﬁc contributing
factor(s) to actin depolymerization speciﬁcally-targeted by eupatilin.
Since it has been shown that cytoskeletal change is coupled to transcrip-
tion (Miralles et al., 2003), the cytoskeletal change induced by eupatilin
Fig. 9. Signiﬁcant amelioration ofOVX-mediated osteoporosis by eupatilin. (A) Scheme for normal disease induction and treatment. (B)Normalmodel; 5OVXmice or 5 SHAMcontrolmice
subjected to initiation of osteoporosis for 4 weeks from ovariectomy followed by oral administration of eupatilin for another 4 weeks. Radiographs of longitudinal and transverse sections
of the proximal femur of OVXmicewere obtainedwith a μ-CT apparatus (upper). (C) Similar parameterswere used formeasuring bone regeneration as described in the LPS-induced bone
lossmodel. (D) Aggressivemodel; 5 OVXmice or 5 SHAMcontrol mice subjected to initiation of osteoporosis for 8weeks fromovariectomy followed by oral administration of eupatilin for
another 4 weeks. E–F) The same measurement for bone regeneration was applied to this aggressive model. Each experiment was performed once. Their statistics were measured with
INFINITT-Xelis software. **P b 0.01 and ***P b 0.001 versus SHAM group, and #P b 0.05, ##P b 0.01, and ###P b 0.001 versus the OVX group.
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OCs. We believe that cytoskeletal rearrangement coupled to transcrip-
tional repression may be the most plausible mechanism for the
eupatilin-mediated anti-osteoclastogenesis. With respect to cell toxici-
ty, eupatilin exhibited no inﬂuence on viability of bone marrow cells
or amarginal effect on osteoblastogenesis at 50 μM,which is the highest
concentration in our preparation, suggesting thatOCsmight be a prefer-
ential natural target for eupatilin over OB. Our observation that control
mice given oral administration of eupatilin (10 mg/kg) appeared
healthy also suggests that cell toxicity is not associated with eupatilin.
Artemisia herb extracts have been safely used for many inﬂammatory
diseases like gastritis or malaria over a few thousand years (Li and
Wu, 1998). Osteoporosis is an aging-associated disease. And it is also
becoming clear that OCs are believed to be a major player in tumor
bone metastasis (Jones et al., 2006). Osteolysis by metastasized tumor
still requires new therapeutic interventions (Morony et al., 2001). OCs
have been well appreciated to play a pivotal role in bone deformation
acquired by rheumatoid arthritis. Gingivitis is a common disease to
adults, which is associated with inﬂammation-driven differentiation
of OCs (Terheyden et al., 2014). Two outstanding therapeutic featuresassociated with eupatilin are 1) preferential target-speciﬁcity, namely
OCs and 2) robustness of elimination of pathogenic MNCs through
immediate cessation of cytoskeletal change and transcription, leading
to actin depolymerization and disintegration of MNCs. Taken together,
eupatilin could provide a good opportunity permitting a versatile ther-
apeutic modality for a broad range of bone diseases to be developed, as
supported by our ﬁnding that human OCs are affected by eupatilin
in vitro. Also, further study is needed to conﬁrm the in vitro effects of
eupatilin on LPS-induced inﬂammatory osteoclast differentiation.
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